Zofran News - Birth Defects
  • GlaxoSmithKline Pays Billions in Criminal and Civil Penalties for False Claims

    In 2012, U.K.-based pharmaceutical company GlaxoSmithKline (GSK) paid $1 billion to resolve criminal charges (misbranding two products and failing to report safety data on another). The company also paid out an additional $2 billion to settle civil liabilities with the U.S. government for violations of the False Claims Act. Among these violations was the off-label promotion of Zofran, a medication originally intended to treat post-operative nausea in cancer patients undergoing chemotherapy and radiation treatments.

    read more